Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app boost HIV prevention in thai youth?

NCT ID NCT05262426

Prevention Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 09, 2026 · Updated 3 times

Summary

This study is testing a computer-based program called MES-PrEP to help young transgender women in Thailand start and stick with HIV pre-exposure prophylaxis (PrEP). The program provides personalized feedback and information based on each person's confidence and motivation. Researchers will measure how acceptable and easy to use the program is, and whether it improves PrEP adherence over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP) – a computer-delivered behavioral intervention
What this could lead to
If successful, this could provide an effective, scalable way to boost PrEP use among at-risk youth, helping prevent HIV infections.
What could go wrong
This is an early feasibility study with only 145 participants, so results may not apply broadly. The intervention relies on self-reported adherence, which can be inaccurate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

145 people

The number who actually took part.

Started

Dec 2021

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 29 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Aim 1: Transgender women participants Inclusion Criteria: * Age 16-29 years old * Male sex at birth * Self-identifies as woman or transgender women or culturally identifies with the female spectrum * Confirmed HIV-negative status * Self-reported recent history of condomless sex in the past 6 months * Able to understand, read and speak Thai * Either having not started PrEP (Group 1: PrEP naive), currently on PrEP but not adherent to PrEP (taking ≤3 pills/week) in the past month (Group 2: PrEP users) or currently on PrEP with good adherence (Group 3: PrEP users with good adherence). Exclusion Criteria: * Have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent * Have active suicidal ideation or major mental illness (e.g., untreated psychosis or mania) at the time of interview (patients will be referred for treatment) * Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance) Healthcare providers Inclusion Criteria: * Have at least 1-year experience working with HIV-negative transgender women, including providing PrEP prescription and counseling Exclusion Criteria: * None Aim 2: Inclusion Criteria: * Age 16-29 years old * Male sex at birth * Self-identifies as woman or transgender women or culturally identifies with the female spectrum * Confirmed HIV-negative status * Self-reported recent history of condomless sex in the past 6 months * Able to understand, read and speak Thai * Either having not started PrEP (Group 1: PrEP naive), currently on PrEP but not adherent to PrEP (taking ≤3 pills/week) in the past month (Group 2: PrEP users). Exclusion Criteria: * Have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent * Have active suicidal ideation or major mental illness (e.g., untreated psychosis or mania) at the time of interview (patients will be referred for treatment) * Laboratory or clinical findings that would preclude PrEP initiation (e.g., decreased creatinine clearance) * Currently enrolled in another HIV intervention study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-exposure prophylaxis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-exposure prophylaxis

Contacts and locations

Locations

  • Institute of HIV Research and Innovation

    Bangkok, Bangkok, 10330, Thailand

  • Rainbow Sky Association of Thailand

    Bangkok, Bangkok, 10240, Thailand

  • SWING Foundation

    Bangkok, Bangkok, 10500, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.